CriticalAtypical antipsychotic – dibenzodiazepine×HIV protease inhibitor / pharmacokinetic booster
Updated · Methodology
Mechanism
CYP1A2 and CYP3A4 metabolise clozapine almost completely, and CYP2C19 and CYP2D6 contribute to a lesser extent (clozapine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ritonavir is a strong inhibitor of CYP3A and CYP2D6, and according to its SmPC it is likely to raise clozapine blood levels (ritonavir SmPC, European Medicines Agency, EMA). At the same time, ritonavir may induce CYP1A2 and lower the levels of drugs metabolised by this enzyme (EMA). The documents give no figures for the net effect on clozapine. The clozapine SmPC considers an effect of CYP3A4 inhibitors, including protease inhibitors, on clozapine levels unlikely, although a few cases have been reported (AEMPS).
Symptoms
The ritonavir SmPC gives the reason for the contraindication: higher clozapine levels raise the risk of serious blood disorders and other serious adverse reactions (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Seizures with clozapine are dose-related (clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Signs of clozapine overdose include drowsiness, confusion, agitation, delirium, seizures, excess salivation, dilated pupils, blurred vision, low blood pressure, fast heart rate, heart rhythm disorders, respiratory depression and aspiration pneumonia (clozapine SmPC, AEMPS, overdose section). Fever, sore throat and other signs of infection may point to a fall in neutrophils (AEMPS).
Management
The combination is contraindicated: the European ritonavir SmPC names clozapine among the drugs that must not be given with ritonavir, with no condition on the ritonavir dose (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). The nirmatrelvir/ritonavir SmPC (Paxlovid, ritonavir 100 mg every 12 hours for 5 days) is less strict: it says to avoid clozapine unless a multidisciplinary assessment concludes that the combination can be used safely (nirmatrelvir/ritonavir SmPC, EMA). The Spanish clozapine SmPC considers an effect of protease inhibitors on clozapine levels unlikely, although a few cases have been reported. With inhibitors of cytochrome P450 enzymes, it says the clozapine dose may need to be lowered (clozapine SmPC, AEMPS). Caution is also needed after a CYP3A4 inhibitor is stopped, because clozapine levels may fall (AEMPS). The US clozapine label says to use clozapine with caution together with CYP3A4 inhibitors, to monitor the patient closely and to consider reducing the clozapine dose (clozapine prescribing information, US Food and Drug Administration, FDA). During clozapine treatment, monitor the neutrophil count every week for the first 18 weeks, then every month for the next 34 weeks. If fever, sore throat or other signs of infection appear, do a blood test at once (clozapine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Ritonavir (nº registro 81039), sección 4.5 (2025)– AEMPS, CIMA, nº registro 81039, sección 4.5
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Clozapina – Leponex (nº registro 59547), sección 4.5 (2026)– AEMPS, CIMA, nº registro 59547, revisión 06/2026, secciones 4.4 y 4.5
- FDA: Clozaril (clozapine) prescribing information (2025)– FDA, DailyMed, HLS Therapeutics, setid 90876802-0e3a-44c9-9ff7-1754dfbe736a, v21, 06/2025, sections 5.1, 5.4, 5.5, 7.1
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), sección 4.4 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos), revisión 06/2026, secciones 4.3 y 4.4
- EMA: Ficha técnica: Nirmatrelvir/ritonavir (EU/1/22/1625), sección 4.5 (2026)– EMA, Paxlovid 150 mg + 100 mg comprimidos recubiertos con película (Pfizer Europe MA EEIG, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1221625001, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4 y 4.5
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), secciones 4.9 y 5.2 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos, Viatris), revisión 06/2026, secciones 4.9 y 5.2